Recently two new anti-obesity drugs (Hoffman LaRoche's Orlistat® and Abbot's Meridia®) have revolutionized the obesity market. Sales of these drugs have reached several billion dollars per year, demonstrating that the obesity market offers tremendous rewards. ObeTherapy's drugs promise to be more efficient and considerably less likely to elicit side effects. Our products could easily reach sales of several billion dollars per year.